Browsing Tag
Orion Corporation
6 posts
Can ODM-212 validate TEAD inhibition as a viable oncology strategy in mesothelioma?
Can Orion Corporation’s ODM-212 prove TEAD inhibition works in mesothelioma? Discover what this FDA orphan designation really signals.
FDA accepts Bayer’s application to expand NUBEQA’s use in prostate cancer treatment
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for NUBEQA (darolutamide),…
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position…
Ami Organics bolsters collaboration with Fermion, signs agreement for new pharma intermediates
Ami Organics Limited, a global leader in manufacturing advanced pharmaceutical intermediates and specialty chemicals, has signed a definitive…
Ami Organics wins multi-million Euro supply contract from Fermion
Ami Organics has signed a multi-year, multi-tonne agreement with Fermion, a wholly-owned subsidiary of Finland-based Orion Corporation for…
Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s…